---
id: "prereq-tech-transfer"
type: "prereq"
source_timestamps: ["§ 1. Embrace a new model for accelerating drug development."]
tags: ["academia", "ip-management"]
related: ["concept-in-house-accelerators"]
reason: "Required to grasp the structural shift represented by Stanford's IMA and similar in-house accelerators."
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# University Technology Transfer

The authors contrast the proposed **in-house accelerators** with **traditional university technology-transfer initiatives**, assuming the reader knows that traditional tech transfer usually means **passively patenting and licensing** discoveries to external companies rather than **actively developing them internally**.

**Why it's required:** it is the baseline against which [[concept-in-house-accelerators]] and [[entity-stanford-ima]] are defined. **Enrichment note:** the literature increasingly critiques passive **"patent and license"** models as too slow for modern drug development, favoring **active portfolio management** and embedded translational infrastructure.


## Related across articles
- [[concept-aerospace-vertical-integration]]